CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE
PR Newswire•10/11/2026•16:00 ET
0
Key Highlights
- ➤$100 million Apotex transaction closed, shifting Cumberland to clinical development
- ➤NDA planned for ifetroban in DMD cardiomyopathy after FDA pre-NDA meeting
- ➤FIGHT DMD trial showed 5.4-point ejection-fraction improvement, p=0.002
- ➤Q3 net income $77.8 million, including $81.1 million divestiture gain
- ➤Cash and equivalents reached $80.6 million at September 30, 2026
Expert Statements
A.J. Kazimi, CEO of Cumberland Pharmaceuticals
“Our first full quarter as a development-focused company has reinforced the value of concentrating our efforts on our clinical pipeline”
A.J. Kazimi, CEO of Cumberland Pharmaceuticals
“Our team and resources are now dedicated to developing new medicines for unmet medical needs. We have the financial strength and the expertise to pursue our new mission, as we work to create lasting value for patients and shareholders.”
CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE PR Newswire
NASHVILLE, Tenn., Nov. 10, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company developing new products for rare diseases, announced today its third quarter 2026 financial results and provided a company update. Cumberland has announced its decision to submit a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for ifetroban as a potential treatment for the cardiomyopathy associated with Duchenne muscular dystrophy ("DMD").
Get started
Create a free account to read the full story.